Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $6.7 million.

  • Keros Therapeutics' Non Operating Income rose 1717.24% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 2268.96%. This contributed to the annual value of $23.8 million for FY2024, which is 4030.33% up from last year.
  • As of Q3 2025, Keros Therapeutics' Non Operating Income stood at $6.7 million, which was up 1717.24% from $6.9 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Non Operating Income high stood at $7.5 million for Q4 2024, and its period low was -$138000.0 during Q3 2021.
  • For the 5-year period, Keros Therapeutics' Non Operating Income averaged around $3.7 million, with its median value being $3.8 million (2023).
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 15126.58% in 2021, then skyrocketed by 520833.33% in 2023.
  • Over the past 5 years, Keros Therapeutics' Non Operating Income (Quarter) stood at -$98000.0 in 2021, then surged by 2387.76% to $2.2 million in 2022, then soared by 177.07% to $6.2 million in 2023, then rose by 21.18% to $7.5 million in 2024, then decreased by 11.26% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.9 million for Q2 2025, and $6.5 million during Q1 2025.